Cancer, Peritoneal Carcinosis
Conditions
Brief summary
The creation of a prospective clinical-biological base dedicated to peritoneal carcinosis must therefore be able to serve as a support for this essential search for transfer.
Detailed description
The main objective is to improve the knowledge of carcinosis mechanisms to develop a specific treatment. That's why this blood collection and tissue collection is very important for the future, these collection will be permitted to the scientists to develop a research specially for carcinosis.
Interventions
OTHERTissues collections
Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
BIOLOGICALbiological collection
Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
Sponsors
Institut du Cancer de Montpellier - Val d'Aurelle
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient over the age of 18; * Patient managed for peritoneal carcinosis : digestives origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer * Patient eligible for a peritoneal carcinosis treatment : at least one (or more) surgery (s) ;chemotherapy or any treatment for this disease * Patient agree will all study procedure : biological samples & tissues samples * Patient giving informed consent
Exclusion criteria
* Patient not affiliated to Social Protection system * Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons * The level of French is insufficient to consent to the study and to response to the questionnaires * Patient under guardianship * Pregnancy ou breast-feeding women * Patient treated in case of an emergency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who gave their consent to participate in the study | Until the study completion: 4 years | The proportion of patients who consent to participate in the study among the screened patients |
Countries
France
Contacts
Primary ContactAurore MOUSSION
Outcome results
None listed